---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-009490"
form_type: "8-K"
ticker: "CVM"
cik: "0000725363"
company_name: "CEL SCI CORP"
filed_at: "2024-07-26T23:59:59+00:00"
generated_at: "2026-05-31T16:04:43.630091+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CEL-SCI bias analysis confirms Multikine survival benefit; 5-year survival 73% vs 45% in target population

## Summary
- Bias analysis found no confounding baseline parameters; treatment and control arms are balanced, no bias detected.
- Target population (no lymph node, low PD-L1): Multikine 5-year survival 73% vs 45% control; hazard ratio 0.35.
- Company plans 212-patient confirmatory registration study with FDA agreement.
- Entire Phase 3 study of 923 patients also showed no bias; CEO notes high confidence in repeating survival benefit.

## SEC filing metadata
- accession: 0001654954-24-009490
- form_type: 8-K
- ticker: CVM
- cik: 0000725363
- company_name: CEL SCI CORP
- filed_at: 2024-07-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/725363/000165495424009490/0001654954-24-009490-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/725363/000165495424009490/cvm_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-009490
- JSON: https://secwatch.observer/filing/0001654954-24-009490.json
- Plain text: https://secwatch.observer/filing/0001654954-24-009490.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.